Jordan Gauthier

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Also affiliated with Seattle Cancer Care Alliance, University of Washington, University of Washington Medical Center, Fred Hutch Cancer Center

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 23 papers. Top paper: “γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial”.

γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial

The Lancet Oncology(2023)10.1016/s1470-2045(23)00246-2

N/A

2.5DataRank · unranked

101 citations

Margot J. Pont, Blythe Sather, Cameron J. Turtle, Brian G. Till, Edward N. Libby +15 more

Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

Blood Advances(2023)10.1182/bloodadvances.2023011287

N/A

1.7DataRank · unranked

55 citations

Erik L. Kimble, Jocelyn H. Wright, Salvatore Fiorenza, Jordan Gauthier, Jenna Voutsinas +18 more

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

Blood Advances(2023)10.1182/bloodadvances.2023011399

N/A

0.958DataRank · unranked

34 citations

Aya Albittar, Jennifer J. Huang, Alexandre V. Hirayama, Erik L. Kimble, Andrew J. Portuguese +11 more

Unveiling the autoreactome: Proteome-wide immunological fingerprints reveal the promise of plasma cell depleting therapy

medRxiv(2023)10.1101/2023.12.19.23300188

N/A

0.637DataRank · unranked

7 citations

David Yu, Alysa Rallistan, Müge Kalaycıoğlu, Jim Boonyaratanakornkit, Damian J. Green +28 more

Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL

Blood Advances(2025)10.1182/bloodadvances.2024015314

N/A

0.447DataRank · unranked

10 citations

Emily C. Liang, Jennifer J. Huang, Erik L. Kimble, Alexandre V. Hirayama, Salvatore Fiorenza +15 more

Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

Transplantation and Cellular Therapy(2023)10.1016/j.jtct.2023.04.001

N/A

0DataRank · unranked

140 citations

Emily C. Liang, Qian Wu, Jenna Voutsinas, Pere Barba, Gloria Iacoboni +19 more

Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy

Clinical Infectious Diseases(2023)10.1093/cid/ciad708

N/A

0DataRank · unranked

52 citations

Sarah Ibrahimi, Hu Xie, Elizabeth R Wong, Jessica Hecht, Mandeep K Sekhon +11 more

Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7511

N/A

0DataRank · unranked

1 citations

Alexandre V. Hirayama, Erik L. Kimble, Andrew J. Portuguese, Aya Albittar, Aude G. Chapuis +8 more

Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity

Journal of Clinical Investigation(2024)10.1172/jci180012

N/A

0DataRank · unranked

44 citations

David Yu, Alysa Rallistan, Müge Kalaycıoğlu, Jim Boonyaratanakornkit, Damian J. Green +29 more

Development and validation of predictive models of early immune effector cell–associated hematotoxicity

Blood Advances(2024)10.1182/bloodadvances.2024014455

N/A

0DataRank · unranked

10 citations

Jennifer J. Huang, Andrew J. Portuguese, Valentín Ortiz‐Maldonado, Aya Albittar, Natalie Wuliji +28 more

Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients

Blood(2024)10.1182/blood.2024024145

N/A

0DataRank · unranked

19 citations

Elizabeth M. Krantz, Hu Xie, Sarah Ibrahimi, Erika S. Kiem, Mandeep K Sekhon +13 more

Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity

Bone Marrow Transplantation(2024)10.1038/s41409-024-02278-3

N/A

0DataRank · unranked

17 citations

Kai Rejeski, Teng Fei, Aya Albittar, Jennifer J. Huang, Andrew J. Portuguese +6 more

Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre–Cellular Therapy SARS-CoV-2 Infection

Clinical Infectious Diseases(2024)10.1093/cid/ciae116

N/A

0DataRank · unranked

13 citations

Leah H Yoke, Pavitra Roychoudhury, Patrick W Flaherty, Masumi Ueda Oshima, Amelia Weixler +7 more

COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics

Transplantation and Cellular Therapy(2024)10.1016/j.jtct.2024.08.010

N/A

0DataRank · unranked

6 citations

Elizabeth M. Krantz, Denise J. McCulloch, Marie H. Wilson, Frank Tverdek, Zahra Kassamali Escobar +9 more

The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy

Blood Advances(2025)10.1182/bloodadvances.2024015164

N/A

0DataRank · unranked

5 citations

Patrick W Flaherty, Hu Xie, Mandeep K Sekhon, Clementine Chalal, Terry Stevens‐Ayers +9 more

Eomesodermin+ CD4+ T cells are critical for curative immunotherapy outcomes

Immunity(2025)10.1016/j.immuni.2025.09.004

N/A

0DataRank · unranked

3 citations

Françoise Haeseleer, Olivia G. Waltner, Kate H. Gartlan, Shruti S. Bhise, Simone A. Minnie +18 more

A Practical Guide to Competing Risk Analysis for Transplant and Cell Therapy Research

Transplantation and Cellular Therapy(2025)10.1016/j.jtct.2025.11.003

N/A

0DataRank · unranked

2 citations

Yein Jeon, Qian Wu, Emily C. Liang, Andrew J. Portuguese, Andrés Gómez‐De León +3 more

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Blood(2020)10.1182/blood.2019002936

N/A

0DataRank · unranked

321 citations

Alexandre V. Hirayama, Janaki Purushe, Kevin A. Hay, James Lymp, Daniel H. Li +12 more

Influence of B cell or plasma cell-targeted CAR-T cell therapy on humoral immunity and vaccine immunogenicity: The HICAR study

Research Square(2025)10.21203/rs.3.rs-7061163/v1

N/A

0DataRank · unranked

0 citations

Stosh Ozog, Elizabeth M. Krantz, Karyn Tindbaek, Julián B. Muñoz, Winnie Liu +16 more

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

The Lancet Haematology(2021)10.1016/s2352-3026(20)30429-4

N/A

0DataRank · unranked

360 citations

Neel S. Bhatt, Andrew St. Martin, Muhammad Bilal Abid, Jenni Bloomquist, Roy F. Chemaly +11 more

CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7532

N/A

0DataRank · unranked

5 citations

Aisling Cearley, Paula Perkins, Angela Kirk, Mazyar Shadman, Staci Williamson +10 more

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Blood(2022)10.1182/blood.2021014497

N/A

0DataRank · unranked

54 citations

Nicolas Gazeau, Alexandre V. Hirayama, Joshua A. Hill, Vicky Wu, Aisling Cearley +17 more

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy

Blood Advances(2022)10.1182/bloodadvances.2022008697

N/A

0DataRank · unranked

26 citations

Cassie Chou, Takahiro Miyazaki, Rachel N. Steinmetz, Henna A Di, Simon P. Fraessle +8 more